Nephrological intensive care

Research Group Leader

  • PD Dr. med. Julius J. Schmidt 

 

Research Assistants

  • Angelina Jechalke 
  • Ann-Kathrin Strunk

 

Scientific profile

 The Nephrological Intensive Care Medicine Working Group is concerned with the effects of current extracorporeal procedures in therapy in the intensive care unit, as well as the use of new innovative extracorporeal procedures and other therapeutic approaches for the treatment of septic patients.

Sepsis is a common condition associated with high mortality in internal medicine intensive care. Extracorporeal therapies are increasingly used not only in the treatment of septic complications such as acute renal failure requiring dialysis, but are also being investigated for immunomodulation and pathogen elimination as a therapy for sepsis itself. The aim is on the one hand to measure the extracorporeal elimination of toxins but also of important drugs such as antibiotics, and on the other hand to investigate the possible effectiveness of adsorption and apharesis techniques in the treatment of septic patients. Furthermore, we are concerned with the specific intensive care treatment of special nephrological patient groups (kidney transplant patients, patients with acute renal failure).

 

Selected publications

Eden G, Schmidt JJ, Büttner S, Kümpers P, Hafer C, Rovas A, Koch BF, Schmidt BMW, Kielstein JT. Safety and efficacy of the Seraph® 100 Microbind® Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study. Crit Care. 2022 Jun 17;26(1):181. doi: 10.1186/s13054-022-04044-7. PMID: 35715801. 

Schmidt JJ, Borchina DN, Van't Klooster M, Bulhan-Soki K, Okioma R, Herbst L, Rodríguez DS, Premužić V, Büttner S, Bader B, Serednicki W, Zasada E, Schmitz M, Quabach RA, Hrincheva M, Fühner T, Kielstein JT. Interim analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity filter) registry. Nephrol Dial Transplant. 2022 Mar 25;37(4):673-680. doi: 10.1093/ndt/gfab347. PMID: 34875087 

Gerecke LKV, Schmidt JJ, Hafer C, Eden G, Bode-Böger SM, Martens-Lobenhoffer J, Welte T, Kielstein JT. Fosfomycin single- and multiple-dose pharmacokinetics in patients undergoing prolonged intermittent renal replacement therapy. J Antimicrob Chemother. 2021 Dec 24;77(1):169-173. doi: 10.1093/jac/dkab357. PMID: 34586373 

Schmidt JJ, Strunk AK, David S, Bode-Böger SM, Martens-Lobenhoffer J, Knitsch W, Scherneck S, Welte T, Kielstein JT. Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy. J Antimicrob Chemother. 2019 Apr 1;74(4):997-1002. doi: 10.1093/jac/dky511. PMID: 30624668 

Schmidt JJ, Lueck C, Ziesing S, Stoll M, Haller H, Gottlieb J, Eder M, Welte T, Hoeper MM, Scherag A, David S. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years. Crit Care. 2018 Nov 19;22(1):307. doi: 10.1186/s13054-018-2221-8. PMID: 30454031; PMCID: PMC6245758. 

 

Current third-party funding

Safety and Performance Evaluation of the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) for Reducing Bacteremia in Patients on Hemodialysis 

Sponsor: Exthera Medical, CA, USA 

 

Entfernung von Fosfomycin durch extrakorporale Verfahren: Single und multiple dose Fosfomycin Pharmakokinetik unter extended dialysis bei Intensivpatienten mit akuter Nierenschädigung und in vitro Adsorption von Fosfomycin durch Cytokinadsorber 

Sponsor: Gemeinschaft der Freunde der MHH 

 

Acute Renal Injury Biomarker Discovery by Nuclear Magnetic Resonance 

Sponsor: Numares AG, Regensburg 

 

Key cooperation partners  

PD. Dr. med. Klaus Stahl, AG Translationale Intensivmedizin, MHH 

PD Dr. med. Benjamin Seeliger, AG Translationale Intensivmedizin, MHH 

Prof. Jan T. Kielstein, Klinkum Braunschweig 

Prof. Sascha David, Universitätspital Zürich und MHH 

 

Contact

E-Mail: schmidt.julius(at)mh-hannover.de